PUBLISHER: DataM Intelligence | PRODUCT CODE: 1374811
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1374811
An external defibrillator is mainly used to treat ventricular fibrillation (fast and irregular heartbeat) and ventricular tachycardia (fatal rapid heartbeat). As an emergency life-saving device, it includes batteries and electrode pads that detect and analyze the patient's heart rhythm and deliver electrical shocks.
Adults can perform external defibrillation using an Automated External Defibrillator (AED) in case of a cardiac arrest. The device provides instructions on how to check the patient's pulse, breathe, and place electrode pads. The AED analyses the patient's heart rhythm, determines if a shock is needed, and guides through cardiopulmonary resuscitation after the shock. The process continues until help arrives to provide advanced life support (ALS) treatment.
AEDs are a type of computerized defibrillator that automatically analyzes the heart rhythm in people who are experiencing cardiac arrest. When appropriate, it delivers an electrical shock to the heart to restore its normal rhythm. The AED system includes accessories, such as a battery and pad electrodes, that are necessary for the AED to detect and interpret a person's heart rhythm and deliver an electrical shock if needed.
Arrhythmias are common, but some types are more common than others. The most common are premature atrial complexes (PACs) and atrial fibrillation. Atrial fibrillation affects about 1 in 50 Americans under the age of 65 and about 1 in 10 Americans over age 65. The incidence of ventricular arrhythmias varies widely. In one study, ventricular arrhythmias occurred in 48 per 100,000 adults (approximately 1 in 2,100 people). In older adults, ventricular arrhythmias occur in 2-3 out of 100 people who do not have any known risk factors, and in 15-16 in 100 people who have coronary artery disease (CAD).
An increasing number of supportive policies by governments, regulatory bodies, and healthcare organizations is anticipated to fuel the market over the forecast period. For example, the IRC (Italian Resuscitation Council) reported that the proposed law on AEDs in Italy was approved by the social affairs commission of the chamber in July 2021.
Furthermore, the global external defibrillators market is driven by various factors like technological advancements, novel product launches, and collaboration with key players will further drive the market growth during the forecast period.
Product recalls is one of the major factor that hampers the market growth rate during the forecast period. For instance, in July 2023, Medtronic recalled implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillators (crt-ds) with glassed feedthrough for risk of low or no energy output during high voltage therapy.
Also, factors such as stringent regulations and lack of awareness and early corrective measures about Sudden Cardiac Arrest (SAC) may hinder the growth of the market over the forecast period. Moreover, Cybersecurity is another major concern in the defibrillators market. The new generation of implantable defibrillators is technologically advanced, allowing for remote data transfer.
The global external defibrillators is segmented based on product type, technology, end-user and region.
The automated external defibrillators segment from the product type accounted for 41.2% and it is expected to be dominated during the forecast period. An automated external defibrillator AED is a portable medical device that delivers a shock to the heart through the chest wall in order to restore normal heart rhythm. AEDs are used to treat victims of sudden cardiac arrest (SCA), which is when the heart stops beating unexpectedly. When someone who is suffering from life-threatening arrhythmias goes into sudden cardiac arrest, time is critical.
Automated external defibrillators (AED) are mostly found in public access settings and are meant to be used by non-medical personnel. If someone suffers sudden cardiac arrest, people nearby can provide CPR and use an AED before the ambulance arrives. When turned on, the AED will give the user step-by-step directions to deliver a shock if needed. The person using the AED needs to follow the instructions and the AED will start functioning automatically. This increases the demand for the AED and accelerates the segment's growth.
For instance, in March 2023, Safe Life acquired Coro Medical and AED.us, a national market player in automated external defibrillator (AED) sales and services, to expand life-saving equipment and services across the United States.
Furthermore, in January 2023, Avive Solutions received FDA approval for its Handheld automated external defibrillator with unique capabilities. Avive Connect AED combines cellular and WiFi connectivity, GPS technology, remote maintenance, and extreme portability in the handheld device.
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to the supportive regulations to increase the availability of public access AEDs, and the high adoption of external defibrillators at healthcare facilities. Many national organizations in the U.S., including the American Heart Association (AHA), recommend the implementation of comprehensive Public Access Defibrillation (PAD) programs.
For instance, in June 2020, Royal Philips, a global leader in health technology, stated that the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration has granted premarket approval (PMA) for the company's HeartStart FR3 and HeartStart FRx automated external defibrillators (AEDs), and their supporting accessories, including batteries and pads.
COVID-19 had a substantial impact on the global external defibrillators market arrhythmias were observed in many COVID patients, but in-hospital defibrillator facilities helped save their lives. Due to the virus outbreak, many surgical procedures were cancelled or postponed, depending on the criticality of the patient. This resulted in losses for companies.
COVID-19 also impacted various stages of the value chain, primarily due to strict lockdowns imposed by the governments of most countries. The turnaround time for the delivery of products and services was also affected due to countries' newer packaging protocols and lockdown measures. All these factors negatively impacted the manufacturing and supply chain of the defibrillators market.
The major global players in the external defibrillators market include: Koninklijke Philips N.V, Advin Health Care, ZOLL Medical Corporation, Defibtech, LLC., Stryker, ClJ Medical System Inc., Avive Solutions, Inc, Schiller AG, MEDIANA Co., Ltd, ViVest Medical Technology Co and among others.
The global external defibrillators market report would provide approximately 69 tables, 70 figures, and 185 Pages.
LIST NOT EXHAUSTIVE